UK nanotechnology firm Midatech, focused on the design, synthesis and manufacture of nanomedicines based on its gold-nanoparticle (GNP) technology, has announced the appointments of Rolf Stahel as chairman and Craig Cook as Chief Operating Officer (COO) and Chief Medical Officer (CMO).
Mr Stahel (pictured) has more than 40 years of experience in the pharmaceutical industry, of which 20 years were spent at CEO and Board level in public and private life science companies across Europe, the US and India.
He was Chief Executive Officer at Shire between 1994 and 2003, during which time he led the company’s listing on the London Stock Exchange in 1996 and development into a global specialty biopharmaceutical company. He joined Shire from Wellcome (now GSK) where he spent 27 years in positions of increasing seniority.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze